Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Neoplasms, Plasma Cell 2Multiple Myeloma 2

Interventions

Dexamethasone 111Cyclophosphamide 99Melphalan 91Bortezomib 69Peripheral Blood Stem Cell Transplantation 64Lenalidomide 58fludarabine phosphate 56Busulfan 54Filgrastim 50Tacrolimus 38Antilymphocyte Serum 38Thalidomide 36Radiotherapy 36Mycophenolic Acid 33fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Whole-Body Irradiation 21Prednisone 21Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 15Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × vatalanib × Plasma cell × Clear all
NCT00240162 2014-09-17

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

Washington University School of Medicine

Phase 2 Terminated
21 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00165347 2007-12-21

Protein Tyrosine Kinases (PTK) in Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
10 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡